Business Description
10x Genomics Inc
NAICS : 621999
SIC : 8099
ISIN : US88025U1097
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 4.08 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -0.47 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 7.31 | |||||
Beneish M-Score | -3.59 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 21.4 | |||||
3-Year EBITDA Growth Rate | 29.9 | |||||
3-Year EPS without NRI Growth Rate | 25.9 | |||||
3-Year FCF Growth Rate | 39.8 | |||||
3-Year Book Growth Rate | -3 | |||||
Future 3-5Y Total Revenue Growth Rate | 13.83 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
9-Day RSI | 0.04 | |||||
14-Day RSI | 0.5 | |||||
12-1 Month Momentum % | -12.12 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.69 | |||||
Quick Ratio | 4.11 | |||||
Cash Ratio | 3.06 | |||||
Days Inventory | 140.22 | |||||
Days Sales Outstanding | 57.64 | |||||
Days Payable | 37.86 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.2 | |||||
Shareholder Yield % | -0.03 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 66.15 | |||||
Operating Margin % | -42.88 | |||||
Net Margin % | -41.23 | |||||
FCF Margin % | -10.44 | |||||
ROE % | -32.81 | |||||
ROA % | -25.79 | |||||
ROIC % | -51.86 | |||||
ROC (Joel Greenblatt) % | -55.27 | |||||
ROCE % | -28.44 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 5.23 | |||||
PB Ratio | 4.43 | |||||
Price-to-Tangible-Book | 4.56 | |||||
EV-to-EBIT | -12.04 | |||||
EV-to-Forward-EBIT | -22.39 | |||||
EV-to-EBITDA | -14.6 | |||||
EV-to-Forward-EBITDA | -26.89 | |||||
EV-to-Revenue | 4.84 | |||||
EV-to-Forward-Revenue | 5.67 | |||||
EV-to-FCF | -46.27 | |||||
Price-to-Net-Current-Asset-Value | 8.84 | |||||
Price-to-Net-Cash | 19.99 | |||||
Earnings Yield (Greenblatt) % | -8.31 | |||||
FCF Yield % | -1.97 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
10x Genomics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil MXN) | 10,822.823 | ||
EPS (TTM) (MXN) | -37.95 | ||
Beta | -0.08 | ||
Volatility % | 21.83 | ||
14-Day RSI | 0.5 | ||
14-Day ATR (MXN) | 0.000019 | ||
20-Day SMA (MXN) | 822.81 | ||
12-1 Month Momentum % | -12.12 | ||
52-Week Range (MXN) | 822.81 - 1018.47 | ||
Shares Outstanding (Mil) | 119.17 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
10x Genomics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
10x Genomics Inc Stock Events
Event | Date | Price(MXN) | ||
---|---|---|---|---|
No Event Data |
10x Genomics Inc Frequently Asked Questions
What is 10x Genomics Inc(MEX:TXG)'s stock price today?
When is next earnings date of 10x Genomics Inc(MEX:TXG)?
Does 10x Genomics Inc(MEX:TXG) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |